Arbutin alleviates diabetic symptoms by attenuating oxidative stress in a mouse model of type 1 diabetes

Abstract

Arbutin is a well-known tyrosinase inhibitor that prevents the formation of melanin through the inhibition of tyrosinase. Therefore, it has been widely used as a cosmetic skin-lightening agent. Arbutin is able to scavenge free radicals within cells and previous studies have found that it also exhibited useful activities for the treatment of diuresis, bacterial infections, and cancer, as well as anti-inflammatory and anti-tussive activities. This study analyzed the effects of arbutin on streptozotocin (STZ)-induced diabetes mellitus in a murine model. Healthy male adult C57BL/6 mice (7 weeks old) were randomly allocated into one of the following three groups of six animals: Normal control with no STZ administration, STZ-induced diabetes, and STZ-induced diabetes treated with 0.3 g/kg/day of arbutin. After 12 days, the levels of insulin, C-peptide, and HbA1c were measured in serum, and the expression and enzymatic activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) were analyzed in pancreatic tissues by western blotting. Arbutin was found to significantly inhibit the increase in blood glucose and the loss of body weight in diabetic mice. Arbutin increased plasma insulin levels in mice with STZ-induced diabetes, whereas there was no detection of insulin in untreated diabetic mice. In addition, there was an increased expression and activity of SOD, CAT, and GPx in diabetic mice treated with arbutin. This investigation demonstrated that arbutin possesses antioxidant activities and can alleviate symptoms of type-1 diabetes mellitus (T1DM) in mice.